- Home
- PMM vs IKT Comparison
PMM vs IKT Comparison
Compare PMM & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PMM | IKT |
|---|---|---|
| Founded | 1989 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 258.7M | 240.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | PMM | IKT |
|---|---|---|
| Price | $6.30 | $2.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 113.0K | ★ 937.9K |
| Earning Date | 01-01-0001 | 03-26-2026 |
| Dividend Yield | ★ 4.68% | N/A |
| EPS Growth | N/A | ★ 57.76 |
| EPS | ★ 0.23 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $27.26 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.77 | $1.33 |
| 52 Week High | $6.52 | $2.27 |
Technical Indicators
Market Signals| Indicator | PMM | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 59.50 | 65.16 |
| Support Level | $6.06 | $1.43 |
| Resistance Level | $6.35 | $2.12 |
| Average True Range (ATR) | 0.07 | 0.11 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 82.14 | 92.55 |
Price Performance
Historical ComparisonAbout PMM Putnam Managed Municipal Income Trust
Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.